Roles at http://pharmaceuticalintelligence.com
Guest Author:
- Pharmaceutical Industry Competitive Intelligence
- Biosimilars
- Biomarkers and medical diagnosis
- Nutrition
- Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics
-
Innovations in Cancer Therapy
Margaret Baker, PhD
meg.baker58@gmail.com
Personal Bio
As a graduate student at Columbia University, I became interested in the impact of oxidative stress on cells and was able to elucidate the generation of peroxide during the metabolism of toxins from fava beans by red blood cells thereby explaining a possible mechanism of hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase deficiency. At UC Davis, I continued to explore oxido-reductive mechanisms in work on the role of selenium-dependent glutathione peroxidase activity in rheumatoid arthritis and inhibition by gold salts.
My interest in free-radical mechanisms led to a post-doc at Stanford University, where my team worked on radiation-mimetic drugs and showed that the compound now known as tirapazamine, is able to act as a single electron acceptor and cause ionizing radiation-like damage to cells, particularly the DNA, under hypoxic conditions as in tumors. I worked as a researcher and project director on a number of aspects of thiol-dependent cellular damage while an Asst ProF at U Penn, and, in pharmaceutical drug discovery on various methods of action that lead to cellular damage up at small biotech companies until 1996.
After several years in competitive intelligence and market research, I became a patent agent (2000) and have been supporting small and large molecule drug discovery by capturing, creating and managing intellectual property. I worked for Johnson & Johnson’s antibody discovery company, Centocor, for 11 years, at which time it was absorbed into Janssen R&D. I supported IP and patent strategies for novel biopharmaceuticals, mostly monoclonal antibodies. I have reviewed patent rights for 30+ biopharmaceutical licensing opportunities and drafted over 80 complex biotechnology and biopharmaceutical patents and assisted in prosecution and defense of patents.
I continue to seek out and to support innovative technologies and educate and assist inventors in protecting their intellectual property.
SKILLS & COMPETENCIES
Patent Agent with 15 years of large and small pharma industry experience in intellectual property support for new product development, licensing and acquisition opportunities. Extremely strong technical expert. Readily masters complexity and able to organize complex information into coherent documents. Direct experience in creating or expanding, evaluating, and defending the intellectual property related to biopharmaceuticals; mining discovery research activities for patentable inventions; providing design around strategies for patents and biosimilars; and preparing new cases. Able to provide insight and input to strategic marketing using competitor IP and other business information. Experienced in interpreting and enforcing IP policy.
- Manages Performance
- Oral and Written Communication
- Technical Expertise
- Analytical Thinking
- Forward Thinking
- Strategic Thinking
- Initiative
- Self Confidence
- Thoroughness
- Personal Credibility
- Flexibility
2001-2012 PATENT LIAISON, J&J Corporate Law Department
On-site at Janssen R & D, Inc., Radnor, PA
Drafted over 80 patents and supported entry of internal and external biopharmaceutical products into the oncology pipeline. Provided due diligence for a $50 million dollar platform technology company acquisition and numerous candidate licensing opportunities. Able to present complex intellectual property issues to discovery scientists and business development. Maintained a front-line role in enforcement of corporate intellectual property policy.
1997-2001 DIRECTOR, Competitive and Technical Intelligence
QED Technologies, Inc. Malvern, PA
Provided decision making and strategic planning support for executives in the biotechnology and biomedical industry with a focus in the area of patent services. Intellectual property due diligence and competitive technical and market analyses for new business, product or technology development and in- or out-licensing opportunities for start-ups, academics, and a multi-national corporation.
1996 – 1997 CONSULTANT: Defined Healthcare Research, Summit, NJ
Primary market research for new pharmaceuticals, new dosage forms, medical devices; some forecasting and market analysis. (less than 1 year)
1993-1996 DIRECTOR, Biology (‘95), Sr. Investigator (‘94), Investigator (‘93)
Zynaxis, Inc., 371 Phoenixville Pike, Malvern, PA 19355
Managed 8 biologists and animal technicians in this startup company developing a novel drug delivery technology based on chemical conjugates of membrane seeking lipids. Established and monitored collaborations with academic and corporate researchers. Prepared disclosure documents, manuscripts, and press statements.
EDUCATION
Ph.D. University of California, Davis, California
Nutrition with minors in Pharmacology and Physiological Chemistry,
Dissertation: Gold and selenium interactions in Rheumatoid Arthritis
M.S. Columbia University, New York, New York, Human Nutrition, Thesis: Peroxide production by Fava bean toxins
A.B. University of California, Berkeley, California, Biochemistry
LICENSES
Registered Patent Agent, License No. 45,868
ACADEMIC EXPERIENCE
Appointments
ASSISTANT PROFESSOR of Radiation Biology
Joint appointment in Biochemistry and Biophysics
University of Pennsylvania School of Medicine
Department of Radiation Oncology, Philadelphia, PA 19104
RESEARCH ASSOCIATE, Department of Radiation Oncology
Stanford University Medical School, Stanford, CA 94305
Technical
Stanford Univ and Univ Penn – radiation and oxidative damage and repair (7 years)
University of Sassari, Sardinia, Italy – mechanisms of red cell oxidation in Favism
Columbia University in Preventive Dentistry – isolated the major glycoprotein from saliva
University of California, Davis – 2 years research on agriculturally important bacteria
University of Vienna – 2 years as research assistant in elements of the cytoskeleton
Teaching Positions
Philadelphia Community College – Anatomy and physiology
University of California, Davis – Physiological Chemistry (Associate), Nutritional Biochemistry (lecturer)
Peace Corps in Ghana, West Africa – General Biology teach for Forms IV through VI
PATENTS
U.S. Patent No. 5,480,901 (Filed Oct. 7, 1994, issued Jan. 2, 1996) Margaret A. Baker and Betsy M. Ohlsson-Wilhelm “Method for Reducing Unwanted Cellular Adhesions”
U.S. Patent No. 5,635,479 (Filed Aug. 31, 1992, issued June 12, 1997) Leonard S. Jacob, W. Lee Maloy, and Margaret A. Baker “Treatment of Gynecological Malignancies with Biologically Active Peptides”
PATENTS AND PATENT APPLICATIONS PREPARED FROM SCRATCH: Approximately 80
Selected Patent Publications
US6995245 Formation of novel erythropoietin conjugates using transglutaminase
WO06062779A2 Anti-integrin immunoconjugates, methods and uses
US7790405 Solution phase biopanning method using engineered decoy proteins
WO2009140186A1 Methods of preparing petide derivatives
WO2011014349A1 Serum markers predicting clinical response to anti-TNFα antibodies in psoriatic arthritis
WO2011115884A1 Diagnostic for lung cancer using miRNA
OTHER ACTIVITIES
J&J World Wide Patent Liaison subcommittee Chairperson from 2003 to 2005, including in organizing and chairing semi-annual meetings. Co-Chaired J&J World Wide Patent Liaison subcommittee Meeting Oct. 2010
Organized and chaired a 2-day workshop for Pharmaceutical Patent Agents within J&J Corporate Legal Department 2006.
Invited lecture: Philadelphia Inventors Symposium, May 15, 2010 Drexel University, “Preparing an Invention Disclosure and Working with a Patent Professional”.
PUBLICATIONS
PUBLICATIONS (23):
- Lacey, E., Brigham-Burke, M., and Baker, M.A. Free sulfhydryl measurement as an indicator of antibody stability. Anal. Biochem.2008, 382, 66–68.
- Baker, M.A., Gray, B.D., Ohlsson-Wilhelm, B.M., Carpenter, D.C., and Muirhead, K.A. Zyn-Linked colchicines: Controlled-release lipophilic prodrugs with enhanced antitumor efficacy. J. Controlled Release 40: 89-100, 1996.
- Esworthy, R.S., Baker, M.A., and Chu, F.-F. Expression of selenium-dependent glutathione peroxidase in human breast tumor cell lines. Cancer Res. 55: 957-962, 1995.
- Baker, M.A., Maloy, W.L., Zasloff, M., and Jacob, L.S. Antitumor activities of Magainin2 and analogue peptides. Cancer Res. 53: 3052-3057, 1993.
- Baker, M.A., and He, S.Q. Elaboration of cellular DNA breaks by hydroperoxides. Free Radical Biol. Med. 11: 563-572, 1991.
- Baker, M.A., Cerniglia, G., and Zaman, A. Microtiterplate assay for measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal. Biochem. 190(2): 360-365, 1990.
- Baker, M.A. Prevention of peroxide produced DNA strand scission in human tumor cells by lipoxygenase inhibitors. Proceedings of the 1st International Conference on Eicosanoids and Bioactive Lipids in Cancer & Radiation Injury, Detroit, MI Oct. 1989. (K.V. Honn, L.J. Marnett, S. Nigam, and T. Walden, eds), Kluwer Academic Publishers, Boston, pp. 73-78, 1991.
- Baker, M.A. and Hagner, B.A. Diamide induced shift in protein and glutathione thiol:disulfide status delays DNA rejoining after X-irradiation of human cancer cells. Biochim. Biophys. Acta 1037: 39-47, 1990.
- Costa, A.K., Baker, M.A., Brown, J.M., and Trudell, J.R. In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res. 49: 925-929, 1989.
- Zeman, E.M., Baker, M.A., Lemmon, M.J., Pearson C.I., Adams, J.S., Brown, J.M., Lee W.W., and Tracy, M. Structure-activity relationships for benzotriazine di-N-oxides. Int. J. Radiat. Oncol. Biol. Phys. 16:977-981, 1989.
- Baker, M.A., Zeman, E.M., Hirst, V.K., and Brown, J.M. Metabolism of SR 4233 by Chinese Hamster Ovary cells: the basis of selective hypoxic cytotoxicity. Cancer Res. 48:5947-5952, 1988.
- Baker, M.A., Taylor, Y.C., and Brown, J.M. Radiosensitization, thiol oxidation, and inhibition of DNA repair by SR 4077. Radiat. Res. 113:346-355, 1988.
- Baker, M.A., and Tappel, A.L. Effects of ligands on gold inhibition of selenium glutathione peroxidase. Biochem. Pharmac. 35:2417-2422, 1986.
- Baker, M.A., and Tappel, A.L. Effect of gold thioglucose on subcellular selenium distribution in rat liver and kidney. Biol. Trace Element Res. 9:113-123, 1986.
- Dillard, C.J., Baker, M.A., Gavino, V.C., Tappel, A., and Tappel, A.L. Effect of dietary selenium and injected gold thioglucose on adjuvant-treated rats. Drug-Nutrient Interac. 3:153-163, 1985.
- Baker, M.A., Dillard, C.J., Tappel, A.L. Effect of gold on selenium and glutathione peroxidase activities in rat tissues. Drug-Nutrient Interac. 3:141-152, 1985.
- Baker, M.A. Goldthioglucose as a selenium antagonist and inhibitor of selenium glutathione peroxidase: in vitro and in vivo interactions. Ph.D. Thesis. University of California, Davis, 1985.
- Baker, M.A., Bosia, A., Pescarmona, G.P., Turini, F., and Arese, P. Mechanism of action of divicine in a cell-free system and in glucose-6-phosphate deficient red cells. Toxicol. Path. 12:331-336, 1984.
- Baker, M.A. Favism: Studies on the biochemical mechanism by which the fava bean toxin, divicine, causes oxidative damage in the glucose-6-phosphate dehydrogenase deficient erythrocyte. Masters Thesis. Columbia University, 1983.
- Wiche, G. and Baker, M.A. Cytoplasmic network arrays demonstrated by immunolocalization using antibodies to a high molecular weight protein present in cytoskeletal preparations from cultured cells. Experimental Cell Res. 138: 15-29, 1982.
- Bertoloni, G., and Baker, M.A. Attempt to demonstrate tubulin structures in an acholeplasma strain. In: Microtubules in Microorganisms. pp. 391-399. Cappuccinelli, P., and Morris, R., Eds., Marcel Dekkar, Inc., New York, 1982.
- Wiche, G., Baker, M.A., Kindas-Muegge, I., Leichtfried, F., and Pytela, R. High molecular weight polypeptides from cultured cells and their possible role as mediators of microtubules and microtubule-intermediate filament interactions. In: Microtubules and Microtubule Inhibitors. pp. 189-200. Debrabander, M., and DeMey, J., Eds., Elsevier/North Holland Biomedical Press, Amsterdam, 1980.
- Bisbee, C., Baker, M.A., Wilson, A.C., Hadji-Asimi, I., and Fischberg, M. Albumin phylogeny in African clawed toads (Xenopus). Science 195:85-86, 1977.
ABSTRACTS: 31
Leave a Reply